Cascadian Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cascadian Therapeutics, Inc.
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Emerging Company Profile: Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.
- Large Molecule
- Other Names / Subsidiaries
- Alpine Biosciences
- Oncothyreon, Inc.
- Seattle Genetics, Inc.s